Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
نویسندگان
چکیده
منابع مشابه
Significance of Cross Lineage Antigen Expression in Acute Lymphoblastic Leukemia
Background: Aberrant expression of cross-lineage antigens gives valuable insight into the diagnosis and prognosis of acute leukemia. In countries like India, cytogenetic tests are widely accessible. Exploring the prognostic value of an accessible test is of great importance. Therefore, establishing a population-specific immunophenotype database will enable to design an antibody panel equipped t...
متن کاملbcr-abl rearrangement in adult T-lineage acute lymphoblastic leukemia.
The bcr-abl rearrangement in T-lineage ALL has been rarely described. In the last three years we studied all new patients with ALL at diagnosis by cytogenetic and molecular analysis. Three out of eleven T-lineage ALL patients presented the rearrangement and only one was Philadelphia positive.
متن کاملAsynchronous antigen expression in B lineage acute lymphoblastic leukemia.
Cell surface phenotypes of 113 B lineage acute lymphocytic leukemia (ALL) cases, defined by the presence of HLA-DR and at least one B-cell-specific antigen (either CD19, CD20, or CD22), were compared with antigen-defined stages of normal B lymphocyte development. The cases were first evaluated for expression of HLA-DR, CD19, CD34, CD10, CD20, and CD22 by indirect one-color immunofluorescence. P...
متن کاملAdult Acute Lymphoblastic Leukemia.
Conventional cytotoxic chemotherapy used to treat acute lymphoblastic leukemia (ALL) results in high cure rates in pediatric patients but is suboptimal in the treatment of adult patients. The 5-year overall survival is approximately 90% in children and 30% to 40% in adults and elderly patients. Adults with ALL tend to have higher risk factors at diagnosis, more comorbidities, and increasing age...
متن کاملNovel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia
The past decade witnessed the rapid development of adult B-lineage acute lymphoblastic leukemia (ALL) treatment. Beyond the development of chemotherapy regimens, immunotherapy is starting a new era with unprecedented complete remission (CR) rate. Targeting B-lineage-specific surface markers such as CD19, CD20, CD22, or CD52, immunotherapy has been demonstrating promising clinical results. Among...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: New England Journal of Medicine
سال: 2016
ISSN: 0028-4793,1533-4406
DOI: 10.1056/nejmoa1605085